Johnson & Johnson raises 2026 sales outlook. Johnson & Johnson stock is unchanged

Published on 10/23/2026 at 10:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

J&J raised 2026 guidance on October 13, 2026. Johnson & Johnson stock costs EUR 237.30 on October 23, 2026, unchanged versus the Xetra close.

Guidance and quarterly performance

Johnson & Johnson raised its estimated 2026 reported sales midpoint to USD 101.2 billion on October 13, 2026.
Third-quarter sales reached USD 25.4 billion, up 5.9 percent year over year.
Johnson & Johnson stock trades at EUR 237.30 at 10:48 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.00 percent versus the Xetra close of October 22, 2026.
Market capitalization stood at USD 644.9 billion as of October 22, 2026.

Comic-Illustration eines Wissenschaftlers mit Spritze und Impfstoffampulle — Pop-Art-Comic zeigt lächelnden Wissenschaftler mit Impfstoff und symbolisiert Innovationskraft von Johnson & Johnson, ISIN US4781601046, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at EUR 237.30 at Lang & Schwarz on October 23, 2026 at 10:48 a.m. CEST, 0.00 percent versus the Xetra close of October 22, 2026. On October 13, 2026, the healthcare company raised its 2026 sales and adjusted earnings outlook, according to Johnson & Johnson.

Guidance rises to USD 101.2 billion

The revised full-year reported sales outlook is USD 101.0 billion to USD 101.4 billion, with a midpoint of USD 101.2 billion and growth of 7.4 percent. The adjusted earnings per share range is USD 11.05 to USD 11.15, compared with the previous range of USD 10.96 to USD 11.11.

The guidance change gives investors a clearer benchmark for the final quarter. The company also lifted the midpoint of its adjusted operational sales outlook to USD 100.7 billion, up from USD 100.6 billion in the July 29, 2026 outlook.

What does the growth mean?

Third-quarter reported sales were USD 25.399 billion, up from USD 23.993 billion in the third quarter of 2025, a 5.9 percent increase. Adjusted earnings per share were USD 2.59, while reported earnings per share were USD 0.09 after a one-time special charge tied to talc litigation and recent business development transactions, according to Johnson & Johnson.

The segment mix shows why the outlook is not purely a MedTech story. Innovative Medicine sales increased 7.7 percent to USD 16.757 billion in the third quarter, while MedTech sales rose 2.5 percent to USD 8.642 billion. CNBC reported that MedTech sales missed the USD 8.71 billion analyst estimate.

Stock holds the Xetra level

Johnson & Johnson has a market capitalization of USD 644.9 billion as of October 22, 2026. Its 52-week range is USD 184.66 to USD 281.07, placing the latest primary-market quote below the yearly high while the German euro indication remains unchanged against its Xetra reference.

At Lang & Schwarz, Johnson & Johnson stock was trading at EUR 237.30 on October 23, 2026 at 10:48 a.m. CEST, 0.00 percent versus the Xetra close of October 22, 2026 at EUR 237.30. The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.